Tag Archives: Lycera

January, 2017

• 4 January

  Lycera’s RORgamma Agonist to Begin Phase 1 Trials

  

  NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients with advanced, relapsed, or refractory solid tumors. “We …

  Share

  • Facebook
  • Twitter
  • LinkedIn

June, 2015

• 9 June

  Celgene Enters $105 Million Cancer Immunotherapy Collaboration with Lycera

  

  Celgene has entered into a new cancer immunotherapy deal that could provide privately-held Lycera Corp. up to $105 million-plus. Lycera announced the formation of an exclusive global collaboration with Celgene to advance Lycera’s proprietary pipeline for cancer and immune-mediated diseases. Lycera said that Celgene will license its portfolio of RORgamma …

  Share

  • Facebook
  • Twitter
  • LinkedIn